LaunchTrends: Entyvio Wave 3 (US) measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market one year following launch. The report evaluates physicians’ current awareness and familiarity with vedolizumab, its advantages and disadvantages compared with currently available therapies, the current and anticipated usage of vedolizumab, and promotional activity of vedolizumab.

Questions Answered in This Report:

  • Physicians’ awareness of a novel therapy and their ability to gain familiarity with the agent help drive the potential for prescribing the agent earlier in the treatment algorithm. What is the awareness of and familiarity with vedolizumab among gastroenterologists? Where will vedolizumab fit into the treatment algorithm for patients with moderate to severe UC and CD?

  • Entyvio represents a novel mechanism of action for the treatment of UC and CD. What are the perceived clinical advantages and disadvantages of vedolizumab compared with other marketed therapies used in moderate to severe UC and CD? To what extent is vedolizumab currently being used by surveyed gastroenterologists, and what factors accelerate or temper its growth?

  • Educational efforts are a key factor differentiating prescribers and nonprescribers. What sources do gastroenterologists use and what promotional messages are being employed by Takeda?


Markets covered: United States.

Primary research: 102 surveyed gastroenterologists with 10 qualitative follow-up interviews.

Author(s): Michael Darcy